The content on this site is intended for healthcare professionals only
Dr Martin McCabe presents his study on chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES). rEECur is the first randomised controlled trial in this setting.
The primary outcome was event-free survival (EFS) for the phase III comparison. Secondary outcomes included overall survival (OS), toxicity, and quality of life (QoL).
He concludes the presentation by discussing his findings of the study.
Watch Dr McCabe's interview on the study here
Watch Dr Gralow comment on the study here
Read the news story here
Laser oncosurgery - A new perspective in treating cancer
Saruparib shows encouraging efficacy and safety in mutant advanced solid tumours
Innovative treatments for solid tumours – TTFields as a therapeutic modality
OncoAlert Round Up for September 15-21, 2023
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
The parotid gland; an unusual site of colorectal cancer metastasis
The advantages of IORT for early breast cancer treatment
Durable effect of imatinib and metronomic chemotherapy with capecitabine in pancreatic carcinoma
The pros and cons of breast IORT and ultra hypofractionation (FR)
